1.Sutton ALM, Harper LM, Tita ATN. Hypertensive Disorders in Pregnancy. Obstetrics and gynecology clinics of North America. 2018;45(2):333–47.
2.Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. Journal of obstetrics and gynaecology Canada: JOGC = Journal d’obstetrique et gynecologie du Canada: JOGC. 2014;36(7):575–6.
3.von Dadelszen P, Magee LA. Pre-eclampsia: an update. Current hypertension reports. 2014;16(8):454.
4.Feyereisen E, Mendez Lozano DH, Taieb J, Hesters L, Frydman R, Fanchin R. Anti-Mullerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reproductive biomedicine online. 2006;12(6):695–703.
5.de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertility and sterility. 2002;77(2):357–62.
6.van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertility and sterility. 2005;83(4):979–87.
7.Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. Maturitas. 2009;63(4):280–91.
8.Tehrani FR, Solaymani-Dodaran M, Tohidi M, Gohari MR, Azizi F. Modeling age at menopause using serum concentration of anti-mullerian hormone. The Journal of clinical endocrinology and metabolism. 2013;98(2):729–35.
9.de Kat AC, Verschuren WM, Eijkemans MJ, van der Schouw YT, Broekmans FJ. The association of low ovarian reserve with cardiovascular disease risk: a cross-sectional population-based study. Human reproduction (Oxford, England). 2016;31(8):1866–74.
10.Tehrani FR, Erfani H, Cheraghi L, Tohidi M, Azizi F. Lipid profiles and ovarian reserve status: a longitudinal study. Human reproduction (Oxford, England). 2014;29(11):2522–9.
11.de Kat AC, Broekmans FJ, Laven JS, van der Schouw YT. Anti-Mullerian Hormone as a marker of ovarian reserve in relation to cardio-metabolic health: a narrative review. Maturitas. 2015;80(3):251–7.
12.de Kat AC, Verschuren WM, Eijkemans MJ, Broekmans FJ, van der Schouw YT. Anti-Mullerian Hormone Trajectories Are Associated With Cardiovascular Disease in Women: Results From the Doetinchem Cohort Study. Circulation. 2017;135(6):556–65.
13.Kim C, Pan Y, Braffett BH, Arends VL, Steffes MW, Wessells H, et al. Anti-Mullerian hormone and its relationships with subclinical cardiovascular disease and renal disease in a longitudinal cohort study of women with type 1 diabetes. Women’s midlife health. 2017;3:5.
14.Yarde F, Maas AH, Franx A, Eijkemans MJ, Drost JT, van Rijn BB, et al. Serum AMH levels in women with a history of preeclampsia suggest a role for vascular factors in ovarian aging. The Journal of clinical endocrinology and metabolism. 2014;99(2):579–86.
15.Shand AW, Whitton K, Pasfield A, Nassar N, McShane M, Han X, et al. Evaluation of anti-Mullerian hormone in the first trimester as a predictor for hypertensive disorders of pregnancy and other adverse pregnancy outcomes. The Australian & New Zealand journal of obstetrics & gynaecology. 2014;54(3):244–9.
16.Tokmak A, Guney G, Aksoy RT, Guzel AI, Topcu HO, Kececioglu TS, et al. May maternal anti-mullerian hormone levels predict adverse maternal and perinatal outcomes in preeclampsia? The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2015;28(12):1451–6.
17.Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Sozial- und Praventivmedizin. 2002;47(6):408–26.
18.Diehl CL, Brost BC, Hogan MC, Elesber AA, Offord KP, Turner ST, et al. Preeclampsia as a risk factor for cardiovascular disease later in life: validation of a preeclampsia questionnaire. American journal of obstetrics and gynecology. 2008;198(5):e11–3.
19.Klemmensen AK, Olsen SF, Osterdal ML, Tabor A. Validity of preeclampsia-related diagnoses recorded in a national hospital registry and in a postpartum interview of the women. American journal of epidemiology. 2007;166(2):117–24.
20.Altman DG, Chitty LS. Charts of fetal size: 1. Methodology. British journal of obstetrics and gynaecology. 1994;101(1):29–34.
21.Royston P, Wright EM. How to construct ‘normal ranges’ for fetal variables. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 1998;11(1):30–8.
22.Royston P, Wright EM. Goodness-of-fit statistics for age-specific reference intervals. Statistics in medicine. 2000;19(21):2943–62.
23.Tehrani FR, Mansournia MA, Solaymani-Dodaran M, Azizi F. Age-specific serum anti-Mullerian hormone levels: estimates from a large population-based sample. Climacteric: the journal of the International Menopause Society. 2014;17(5):591–7.
24.Brown MA, Lindheimer MD, de Swiet M, Assche AV, Moutquin J-M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Taylor & Francis; 2001.
25.Amiri M, Tehrani FR, Rahmati M, Behboudi-Gandevani S, Azizi F. Changes over-time in blood pressure of women with preeclampsia compared to those with normotensive pregnancies: A 15 year population-based cohort study. Pregnancy Hypertension. 2019;17:94–9.
26.D’Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Statistics in medicine. 1990;9(12):1501–15.
27.Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002;143(3):1076–84.
28.Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142(11):4891–9.
29.Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Human reproduction (Oxford, England). 2006;21(9):2223–7.
30.Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction (Cambridge, England). 2006;131(1):1–9.
31.Anderson EL, Fraser A, McNally W, Sattar N, Lashen H, Fleming R, et al. Anti-mullerian hormone is not associated with cardiometabolic risk factors in adolescent females. PloS one. 2013;8(5):e64510.
32.Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause (New York, NY). 2006;13(2):265–79.
33.van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347(9003):714–8.
34.Hu FB, Grodstein F, Hennekens CH, Colditz GA, Johnson M, Manson JE, et al. Age at natural menopause and risk of cardiovascular disease. Archives of internal medicine. 1999;159(10):1061–6.
35.Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. The New England journal of medicine. 1998;338(23):1650–6.
36.Chu MC, Rath KM, Huie J, Taylor HS. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Human reproduction (Oxford, England). 2003;18(8):1570–3.
37.Koninger A, Kauth A, Schmidt B, Schmidt M, Yerlikaya G, Kasimir-Bauer S, et al. Anti-Mullerian-hormone levels during pregnancy and postpartum. Reproductive biology and endocrinology: RB&E. 2013;11:60.
38.Koninger A, Schmidt B, Mach P, Damaske D, Niessen S, Kimmig R, et al. Anti-Mullerian-Hormone during pregnancy and peripartum using the new Beckman Coulter AMH Gen II Assay. Reproductive biology and endocrinology: RB&E. 2015;13:86.
39.Ramezani Tehrani F, Mansournia MA, Solaymani-Dodaran M, Steyerberg E, Azizi F. Flexible parametric survival models built on age-specific antimullerian hormone percentiles are better predictors of menopause. Menopause (New York, NY). 2016;23(6):676–81.
40.Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC. Maternal serum anti-Mullerian hormone at 11–13 weeks’ gestation in the prediction of preeclampsia. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2015;28(8):865–8.
41.La Marca A, Volpe A. Anti‐Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clinical endocrinology. 2006;64(6):603–10.
Figure Legends:
Figure 1: Summary of case recruitment for the study
Figure 2: ROC curve for age-specific AMH as a predictor of preeclampsia
Figure 3: Age related (a) and BMI related (b) AMH in women with PE compared with that of a reference group. The serum AMH level is plotted on a logarithmic scale.